• 1
    U.S. Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health. 2nd ed. Washington, D.C.: U.S. Government Printing Office, 2000.
  • 2
    Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999; 341: 11981205.
  • 3
    Cooper GS, Yuan Z, Chak A, Rimm AA. Geographic and patient variation among Medicare beneficiaries in the use of follow-up testing after surgery for nonmetastatic colorectal carcinoma. Cancer. 1999; 85: 21242131.
  • 4
    Greenwald HP, Polissar NL, Borgatta EF, McCorkle R, Goodman G. Social factors, treatment, and survival in early-stage non-small cell lung cancer. Am J Public Health. 1998; 88: 16811684.
  • 5
    Albain KS, Green SR, Lichter AS, et al. Influence of patient characteristics, socioeconomic factors, geography, and systematic risk on the use of breast–sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol. 1996; 14: 30093017.
  • 6
    Hillner BE, Penberthy L, Desch CE, McDonald MK, Smith TJ, Retchin SM. Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treat. 1996; 40: 7586.
  • 7
    Smith TJ, Penberthy L, Desch CE, et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer. 1995; 13: 235252.
  • 8
    Nattinger AB, Gottlieb MS, Veum J, Yahnke D, Goodwin JS. Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med. 1992; 326: 11021107.
  • 9
    Roetzheim RG, Pal N, Gonzales EC, Ferrante J, Van Durme DJ, Krischer JP. Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health. 2000; 90: 17461754.
  • 10
    NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264: 14441450.
  • 1
    National Institutes of Health, National Cancer Institute. CancerNet: Treatment Options for Health Professionals. Available at url: [accessed on September 15, 2000].
  • 12
    SEER Program comparative staging guide for cancer version 1.1. Publication number 93-3640. U.S. Department of Health and Human Services: Washington, DC, 1993.
  • 13
    Jaro MA. Probabilistic linkage of large public health data files. Stat Med. 1995; 14: 491498.
  • 14
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613619.
  • 15
    Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity. J Chronic Dis. 1987; 40: 373404.
  • 16
    Physicians' desk reference. 51st ed. In: SiftonD.W., editor. Montvale, NJ: Medical Economics Company, 1997.
  • 17
    Breslow NE. Extra-Poisson variation in log-linear models. Appl Stat. 1984; 33: 3844.
  • 18
    McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman and Hall, 1989.
  • 19
    Sugarman J. Improving American Indian cancer data in the Washington state cancer registry using linkages with the Indian Health Service and Tribunal Records. Cancer. 1996; 78: 15641568.
  • 20
    Campo J, VanEenwyk J, O'Connor C, Spadt V, LeMier M. Annual report of the Washington State Cancer Registry: 1997 Cancer in Washington. Olympia, Washington: Washington State Department of Health, 1999.
  • 21
    Vernon SW, Hughes JI, Heckel VM, Jackson GL. Quality of care for colorectal cancer in a fee-for-service and health maintenance organization practice. Cancer. 1992; 69: 24182425.
  • 22
    Merrill RM, Brown ML, Potosky AL, et al. Survival and treatment for colorectal cancer Medicare patients in two group/staff health maintenance organizations and the fee-for-service setting. Med Care Res Rev. 1999; 56: 177196.
  • 23
    Cancer Patient Data Program. SEER 1997: Seattle case completeness and data validity audit [review]. San Francisco: University of California, San Francisco, 1998.
  • 24
    North American Association of Central Cancer Registries. Case completeness and data quality audit: Washington State Cancer Registry. North American Association of Central Cancer Registries, Cancer Surveillance and Control Program, On-site Audit: September 1998.
  • 25
    Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of Stage III colon carcinoma: a final report. Ann Intern Med. 1995; 122: 321326.
  • 26
    International multicentre pooled analysis of colon cancer trials investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995; 345: 939944.
  • 27
    O'Connell M, Mailliard J, Macdonald J, et al. An intergroup trial of intensive course 5FU and low dose leucovorin as surgical adjuvant therapy for high risk colon cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol. 1993; 12: A552.
  • 28
    Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990; 322: 352358.
  • 29
    HewittM, SimoneJV, editors. Ensuring Quality Cancer Care. Washington, DC: National Academy Press, 1999.